ARC-520

November 10, 2016November 10, 2016

FDA Places Hold on Arrowhead’s Phase 2 HBV Clinical Trial

Hepatitis B, News

The U.S. Food and Drug Administration (FDA) placed a hold on Arrowhead Pharmaceuticals‘ Heparc-2004 Phase 2 clinical trial evaluating ARC-520, the company’s investigational medicine for the treatment of chronic hepatitis ... Read more

January 23, 2015January 23, 2015

Arrowhead’s Chronic HBV Infection Therapy Study Approved

News

Arrowhead Research Corporation has been cleared to start its modified multiple-dose study of ARC-520 in patients who suffer from chronic hepatitis B infection by the U.S. Food and Drug Administration (FDA). The ... Read more

October 9, 2014October 9, 2014

Anticipation Grows Over New Data For Experimental Hepatitis B Therapy

Hepatitis B, News

There is a great deal of anticipation surrounding the latest results from Arrowhead Research Corporation, who are preparing to present the latest results from their ongoing Phase 2a trial of ARC-520, their ... Read more